Early detection and prognosis of ovarian cancer using serum YKL-40 Journal Article


Authors: Dupont, J.; Tanwar, M. K.; Thaler, H. T.; Fleisher, M.; Kauff, N.; Hensley, M. L.; Sabbatini, P.; Anderson, S.; Aghajanian, C.; Holland, E. C.; Spriggs, D. R.
Article Title: Early detection and prognosis of ovarian cancer using serum YKL-40
Abstract: Purpose: YKL-40 is a secreted glycoprotein (chitinase family). We compared YKL-40 with two ovarian cancer serum markers, CA125 and CA15-3, for the detection of early-stage ovarian cancer. Materials and Methods: Serum YKL-40 levels were assayed by enzyme-linked immunosorbent assay for 46 healthy subjects, 61 high-risk individuals, 33 patients with benign gynecologic processes, and 50 preoperative patients subsequently diagnosed with predominantly early-stage ovarian cancer. Serum CA125 and CA15-3 values were obtained. Results: Median YKL-40 level was 28 ng/mL (range, 15 to 166 ng/mL) for healthy subjects, 36 ng/mL (range, 9 to 69 ng/mL) for high-risk individuals without prior cancer, 44.5 ng/mL (range, 5 to 133 ng/mL) for high-risk patients with prior breast cancer, and 38 ng/mL (range, 5 to 67 ng/mL) for individuals with benign gynecologic processes (P = NS). Median preoperative YKL-40 level for ovarian cancer patients was 94 ng/mL (range, 17 to 517 ng/mL; P < .0001 compared with normal and high-risk). YKL-40 was elevated (≥ 62 ng/mL) in 36 (72%) of 50 patients compared with 23 (46%) of 50 and 13 (26%) of 50 patients for CA125 and CA15-3 (P < .008). Twenty (65%) of 31 early-stage patients had elevated serum YKL-40 levels compared with 11 (35%) of 31 and four (13%) of 31 patients for CA125 and CA15-3 (P = .039). YKL-40 levels increased with stage (P < .005), regardless of grade, histology, or patient age. Patients with early-stage tumors with YKL-40 values more than 80 ng/mL had a worse prognosis (71 % recurrence v no recurrence [P = .0341). Conclusion: YKL-40 may represent a novel marker for the detection of early-stage ovarian cancer. YKL-40 levels in early-stage patients may also predict disease recurrence and survival. The utility of YKL-40 in detection of early-stage ovarian cancer deserves further investigation. © 2004 by American Society of Clinical Oncology.
Keywords: survival; adult; cancer survival; human tissue; aged; aged, 80 and over; middle aged; survival analysis; unclassified drug; clinical trial; cancer risk; cancer patient; comparative study; cancer staging; methodology; neoplasm staging; sensitivity and specificity; ovarian neoplasms; biological marker; protein blood level; ovary cancer; neoplasm recurrence, local; breast cancer; tumor markers, biological; pathology; tumor marker; enzyme linked immunosorbent assay; histology; high risk patient; tumor recurrence; ovary tumor; autoantigen; autoantigens; recurrent disease; ca 125 antigen; enzyme-linked immunosorbent assay; gynecology; glycoproteins; glycoprotein; ca 15-3 antigen; humans; prognosis; human; female; priority journal; article; ykl 40 glycoprotein; chi3l1 protein, human
Journal Title: Journal of Clinical Oncology
Volume: 22
Issue: 16
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2004-08-15
Start Page: 3330
End Page: 3339
Language: English
DOI: 10.1200/jco.2004.09.112
PROVIDER: scopus
PUBMED: 15310777
DOI/URL:
Notes: J. Clin. Oncol. -- Cited By (since 1996):84 -- Export Date: 16 June 2014 -- CODEN: JCOND -- Source: Scopus
Altmetric Score
MSK Authors
  1. Noah Kauff
    122 Kauff
  2. Jakob Dupont
    64 Dupont
  3. Paul J Sabbatini
    199 Sabbatini
  4. Eric Holland
    219 Holland
  5. Martee L Hensley
    220 Hensley
  6. David R Spriggs
    312 Spriggs
  7. Martin Fleisher
    237 Fleisher
  8. Howard T Thaler
    191 Thaler
  9. Meena Tanwar
    4 Tanwar